Xilio Therapeutics, Inc.

Xilio Therapeutics has filed two officer departure 8-Ks in the past 90 days, signaling potential leadership instability at the biotech firm. While our detection window shows no cyber incidents, the dual departures warrant closer examination of timing, roles, and any related compensation or strategic shifts. The full $49 Report adds dilution risk scoring, detailed 8-K context analysis, 12-month financing history, and AI-driven risk signals across governance and capital structure to assess whether these changes reflect normal transitions or material concerns for equity investors.